We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ingeborg
Welters
anwei@liverpool.ac.uk
Mrs
williams
karen
Karen.Williams@liverpoolft.nhs.uk
Miss
Heather
Rogers
heather.rogers@liverpoolft.nhs.uk
More information about this study, what is involved and how to take part can be found on the study website.
Other bacterial diseasesCerebrovascular diseasesOther forms of heart diseaseOther diseases of the respiratory system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Atrial fibrillation (AF) is condition where the heartbeat becomes fast and irregular. AF can be a complication of acute illness. Even short episodes of AF, double the risk of developing blood clots or a stroke.
We wish to understand which patients have a high risk of developing it. Using modern compute technology (“artificial intelligence”), computer scientists can develop tools that update in real time when receiving patient data to inform health care professionals about the risk for AF. This would allow doctors to take measures to prevent AF or to request further investigations. In this project, we wish to collect data to develop such a tool, also called “digital twin”. Testing of this digital twin in patients will be part of a follow-up study. We wish to collect this data using an approved and licensed wireless monitoring system.
Patients over 50 years old admitted to hospital for acute illness can take part. Patients will have heart rate, breathing rate, blood pressure and oxygen levels measured as per the normal hospital practice. Patients will also wear a wireless patch measure heart rate and rhythm for up to 7 days.
We will enrol 25 patients in a second part of the study where alerts for any abnormal readings will be sent to the ward nurse on a mobile phone. In questionnaires or interviews we will ask these patients and the nursing staff for their opinions the extra monitoring and how useful the alerts are in improving patient care.
NOTE-AF is part of a large project called “TARGET” to improve care and reduce strokes caused by AF funded by the European Union. The overall aim of TARGET is to prevent and better treat AF and stroke using digital twins.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Active Monitoring;
You can take part if:
You may not be able to take part if:
1) Atrial fibrillation or atrial flutter at the time of screening 2) Patients in atrial fibrillation or atrial flutter at time of preoperative assessment or admission to hospital 3) Paced cardiac rhythm 4) Inability to obtain consent (patient and/or consultees decline study participation) 5) Allergy to plaster or silicone 6) Expected hospital stay < 48h
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Miss
Heather
Rogers
heather.rogers@liverpoolft.nhs.uk
Mrs
williams
karen
Karen.Williams@liverpoolft.nhs.uk
Ingeborg
Welters
anwei@liverpool.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by LIVERPOOL UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by UK Research and Innovation (UKRI) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 62795
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
